Press Room

12th Global Drug Delivery & Formulation Virtual Summit

Start
Monday, March 15, 2021 - 00:00
End
Wednesday, March 17, 2021 - 00:00
Location: online
Drug Delivery Formulation | Hovione

At Hovione we are constantly innovating to find better and more efficient ways of doing things.

Visit Hovione’s booth at the 12th Global Drug Delivery and Formulation Summit (DDF) and meet our team of experts.

Learn more about ASD-HIPROS – the most advanced and accurate screening platform able to identify the most efficient and stable Amorphous Solid Dispersion formulations by Spray Drying. Requiring as little as 5g of API and in just 6 weeks, this platform maximizes your chances of identifying a successful formulation, accelerating development towards commercial manufacturing and patient availability.

Schedule a meeting button | Hovione

Don’t miss our “Technology & Innovation” Session

Featured Speakers: Mafalda Paiva - Group Leader, R&D Analytical Development and João Henriques - Group Leader, R&D Drug Product Development

Title: Performance Enhancement Strategies for Low Solubility APIs – do more with less
Session Track: Technology & Innovation
Date: Wednesday, March 17, 2021
Time: 09:25AM – 10:00AM GMT

Abstract: The presentation will address the main challenges in the formulation of ASDs, highlighting the importance of integrated development and the synergies between pre-formulation and commercial manufacturing expertise. Mafalda and João will also be presenting ASD HIPROS, our new state-of-the-art, science-based development platform for ASDs.

Conference Website: httpss://www.ddfevent.com/ 

12th Global Drug Delivery & Formulation Virtual Summit | Hovione

 

 

Interested in turning your most difficult challenge into a successful solution?

 

 

Schedule a meeting with our experts

 

 

You might be interested in:

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025